{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:16:11Z","timestamp":1788322571747,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T00:00:00Z","timestamp":1681603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>For patients with cancer of unknown primary (CUP), treatment options are limited. Precision oncology, the interplay of comprehensive genomic profiling (CGP) and targeted therapies, aims to offer additional treatment options to patients with advanced and hard-to-treat cancers. We aimed to highlight the use of a molecular tumor board (MTB) in the therapeutic management of CUP patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center observational study, CUP patients, presented to the MTB of the Comprehensive Cancer Center Munich LMU, a tertiary care center, were analyzed retrospectively. Descriptive statistics were applied to describe relevant findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between June 2016 and February 2022, 61 patients with unfavorable CUP were presented to the MTB, detected clinically relevant variants in 74% (45\/61) of patients, of which 64% (29\/45) led to therapeutic recommendation. In four out of 29 patients (14%), the treatment recommendations were implemented, unfortunately without resulting in clinical benefit. Reasons for not following the therapeutic recommendation were mainly caused by the physicians\u2019 choice of another therapy (9\/25, 36%), especially in the context of worsening of general condition, lost to follow-up (7\/25, 28%) and death (6\/25, 24%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CGP and subsequent presentation to a molecular tumor board led to a high rate of therapeutic recommendations in patients with CUP. Recommendations were only implemented at a low rate; however, late GCP diagnostic and, respectively, MTB referral were found more frequent for the patients with implemented treatment. This contrast underscores the need for early implementation of CGP into the management of CUP patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-023-04741-y","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T02:02:10Z","timestamp":1681610530000},"page":"8225-8234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective"],"prefix":"10.1007","volume":"149","author":[{"given":"L.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"R\u00fchlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hasselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kumbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rudelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-3754","authenticated-orcid":false,"given":"C. B.","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,16]]},"reference":[{"issue":"18_suppl","key":"4741_CR1","doi-asserted-by":"publisher","first-page":"LBA1006","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA1006","volume":"36","author":"J Baselga","year":"2018","unstructured":"Baselga J, Dent SF, Cort\u00e9s J, Im Y-H, Di\u00e9ras V, Harbeck N et al (2018) Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. J Clin Oncol 36(18_suppl):LBA1006-LBA","journal-title":"J Clin Oncol"},{"issue":"26","key":"4741_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"8","key":"4741_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/sj.bjc.6604315","volume":"98","author":"J Bridgewater","year":"2008","unstructured":"Bridgewater J, van Laar R, Floore A, Van\u2019T VL (2008) Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 98(8):1425\u20131430","journal-title":"Br J Cancer"},{"issue":"24","key":"4741_CR4","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1200\/JCO.2002.04.019","volume":"20","author":"S Culine","year":"2002","unstructured":"Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A et al (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20(24):4679\u20134683","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"4741_CR5","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G (2015) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v133\u2013v138","journal-title":"Ann Oncol"},{"key":"4741_CR6","doi-asserted-by":"publisher","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","volume":"30","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Maillard A, Penel N, Baciarello G, Allouache D, Daugaard G et al (2019) LBA15_PR - A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol 30:v851","journal-title":"Ann Oncol"},{"issue":"9","key":"4741_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","volume":"4","author":"AM Goodman","year":"2018","unstructured":"Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G et al (2018) Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol 4(9):1237\u20131244","journal-title":"JAMA Oncol"},{"issue":"11","key":"4741_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djt099","volume":"105","author":"FA Greco","year":"2013","unstructured":"Greco FA, Lennington WJ, Spigel DR, Hainsworth JD (2013) Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology. J Natl Cancer Inst 105(11):782\u2013790","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"4741_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R et al (2012) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31(2):217\u2013223","journal-title":"J Clin Oncol"},{"issue":"2","key":"4741_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R et al (2013) Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31(2):217\u2013223","journal-title":"J Clin Oncol"},{"issue":"3","key":"4741_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s41669-017-0051-2","volume":"2","author":"MB Hannouf","year":"2018","unstructured":"Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G et al (2018) The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study. Pharmacoecon Open 2(3):255\u2013270","journal-title":"Pharmacoecon Open"},{"issue":"7","key":"4741_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"H Hayashi","year":"2019","unstructured":"Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K et al (2019) Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol 37(7):570\u2013579","journal-title":"J Clin Oncol"},{"issue":"5","key":"4741_CR13","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","volume":"149","author":"K Heinrich","year":"2023","unstructured":"Heinrich K, Miller-Phillips L, Ziemann F, Hasselmann K, R\u00fchlmann K, Flach M et al (2023) Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU molecular tumor board. J Cancer Res Clin Oncol 149(5):1905\u20131915. https:\/\/doi.org\/10.1007\/s00432-022-04165-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"4741_CR14","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Human Epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748","journal-title":"Mol Biol Int"},{"issue":"5","key":"4741_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.trecan.2020.11.002","volume":"7","author":"S Kato","year":"2021","unstructured":"Kato S, Alsafar A, Walavalkar V, Hainsworth J, Kurzrock R (2021) Cancer of unknown primary in the molecular era. Trends Cancer 7(5):465\u2013477","journal-title":"Trends Cancer"},{"key":"4741_CR16","doi-asserted-by":"publisher","unstructured":"Kato S, Gumas S, Adashek JJ, Okamura R, Lee S, Sicklick JK et al (2022) Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown. Mol Oncol. https:\/\/doi.org\/10.1002\/1878-0261.13293","DOI":"10.1002\/1878-0261.13293"},{"issue":"1\u20132","key":"4741_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000513847","volume":"44","author":"D Koeberle","year":"2021","unstructured":"Koeberle D, Fritsch R (2021) Targeting HER2 in biliary tract carcinomas: challenges and opportunities. Oncol Res Treat 44(1\u20132):1\u20133","journal-title":"Oncol Res Treat"},{"issue":"3","key":"4741_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","volume":"34","author":"A Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K et al (2023) Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34 (3):228\u2013246. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.013","journal-title":"Ann Oncol"},{"issue":"11","key":"4741_CR20","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/ijc.32358","volume":"145","author":"J Leichsenring","year":"2019","unstructured":"Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar A-L et al (2019) Variant classification in precision oncology. Int J Cancer 145(11):2996\u20133010","journal-title":"Int J Cancer"},{"issue":"11","key":"4741_CR21","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s12094-018-1899-z","volume":"20","author":"F Losa","year":"2018","unstructured":"Losa F, Iglesias L, Pan\u00e9 M, Sanz J, Nieto B, Fust\u00e9 V et al (2018) 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol 20(11):1361\u20131372","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"4741_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38(1):1\u201310","journal-title":"J Clin Oncol"},{"issue":"6","key":"4741_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard C, Michiels S, Fert\u00e9 C, Le Deley MC, Lacroix L, Hollebecque A et al (2017) High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov 7(6):586\u2013595","journal-title":"Cancer Discov"},{"issue":"1","key":"4741_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"21","key":"4741_CR25","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309\u20135337","journal-title":"Cell"},{"issue":"11","key":"4741_CR26","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP et al (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol 31(11):1491\u20131505","journal-title":"Ann Oncol"},{"issue":"Suppl 10","key":"4741_CR27","doi-asserted-by":"publisher","first-page":"x271","DOI":"10.1093\/annonc\/mds357","volume":"23","author":"KA Oien","year":"2012","unstructured":"Oien KA, Dennis JL (2012) Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol 23(Suppl 10):x271\u2013x277","journal-title":"Ann Oncol"},{"issue":"4","key":"4741_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2018","unstructured":"Ott PA, Bang Y-J, Piha-Paul SA, Razak ARA, Bennouna J, Soria J-C et al (2018) T-cell\u2013inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318\u2013327","journal-title":"J Clin Oncol"},{"issue":"5","key":"4741_CR29","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1002\/onco.13744","volume":"26","author":"C Pauli","year":"2021","unstructured":"Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross JS et al (2021) A challenging task: identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience. Oncologist 26(5):e769\u2013e779","journal-title":"Oncologist"},{"issue":"9824","key":"4741_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G (2012) Cancer of unknown primary site. Lancet 379(9824):1428\u20131435","journal-title":"Lancet"},{"issue":"14","key":"4741_CR31","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.ejca.2007.06.023","volume":"43","author":"G Pentheroudakis","year":"2007","unstructured":"Pentheroudakis G, Golfinopoulos V, Pavlidis N (2007) Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 43(14):2026\u20132036","journal-title":"Eur J Cancer"},{"issue":"3","key":"4741_CR32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000457956","volume":"105","author":"A Perren","year":"2017","unstructured":"Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G et al (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105(3):196\u2013200","journal-title":"Neuroendocrinology"},{"issue":"1","key":"4741_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP (2010) Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT. Eur J Nucl Med Mol Imaging 37(1):67\u201377","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"4741_CR34","first-page":"e5552","volume":"11","author":"A Qaseem","year":"2019","unstructured":"Qaseem A, Usman N, Jayaraj JS, Janapala RN, Kashif T (2019) Cancer of unknown primary: a review on clinical guidelines in the development and targeted management of patients with the unknown primary site. Cureus. 11(9):e5552-e","journal-title":"Cureus."},{"issue":"1","key":"4741_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","volume":"1","author":"JS Ross","year":"2015","unstructured":"Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K et al (2015) Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol 1(1):40\u201349","journal-title":"JAMA Oncol"},{"issue":"7","key":"4741_CR36","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cncr.31125","volume":"124","author":"JS Ross","year":"2018","unstructured":"Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J et al (2018) Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 124(7):1358\u20131373","journal-title":"Cancer"},{"key":"4741_CR37","first-page":"21","volume":"347","author":"Y Samuels","year":"2010","unstructured":"Samuels Y, Waldman T (2010) Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347:21\u201341","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"4741_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.15403\/jgld.2014.1121.261.haz","volume":"26","author":"C Tomuleasa","year":"2017","unstructured":"Tomuleasa C, Zaharie F, Muresan MS, Pop L, Fekete Z, Dima D et al (2017) How to diagnose and treat a cancer of unknown primary site. J Gastrointestin Liver Dis 26(1):69\u201379","journal-title":"J Gastrointestin Liver Dis"},{"issue":"3","key":"4741_CR39","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang Y-J, Feng-yi F, Xu JM, Lee K-W, Jiao S-C et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3):476\u2013484","journal-title":"Gastric Cancer"},{"key":"4741_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2017.05.006","volume":"81","author":"L Verlingue","year":"2017","unstructured":"Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Fert\u00e9 C (2017) Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground? Eur J Cancer 81:161\u2013173","journal-title":"Eur J Cancer"},{"issue":"6","key":"4741_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/modpathol.2016.60","volume":"29","author":"Q Xu","year":"2016","unstructured":"Xu Q, Chen J, Ni S, Tan C, Xu M, Dong L et al (2016) Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin. Mod Pathol 29(6):546\u2013556","journal-title":"Mod Pathol"},{"issue":"9","key":"4741_CR42","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jmoldx.2020.06.005","volume":"22","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang Q, Qi P, Chen J, Sun Y, Jin S et al (2020) Development and clinical validation of a 90-gene expression assay for identifying tumor tissue origin. J Mol Diagn 22(9):1139\u20131150","journal-title":"J Mol Diagn"},{"issue":"1","key":"4741_CR43","first-page":"188549","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Zhu X, Wei X, Tang C, Zhang W (2021) HER2-targeted therapies in gastric cancer. Biochim Biophys Acta 1876(1):188549","journal-title":"Biochim Biophys Acta"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04741-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:32:26Z","timestamp":1690475546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,16]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["4741"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04741-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2574066\/v1","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,16]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LW: Honoraria: Roche, Servier, Travel support: AMGEN. KH: Honoraria: Roche, Taiho; consulting or advisory role: BMS, Servier; travel support and expenses: Amgen, Merck, Servier. DK: Honoraria: AstraZeneca; Travel support: Servier, GSK, and BMS. JK: Honoraria and reimbursement for travel and accommodation for participants in advisory boards and from speaker\u2019s bureau from AstraZeneca, Novartis, Roche Pharma. WGK: Consulting and advisory role: BMS. DR: Honoraria: Bayer, Ipsen; Travel support: Ipsen. LH: Research support from Therakos; speakers and advisory board honoraria from 4SC, Amgen, BiomeDx, Bristol Myers Squibb, Curevac, Merck, Merck Sharp & Dohme, Myoncare, Novartis, Pierre Fabre, Sanofi, SUN and Roche. Patents (a) intra-tumoral administration of IL-12 encoding nucleic acid molecules; Publication No.: WO\/2001\/052874; PCT\/EP2001\/000363; (b) preventing secondary lymphedema with vegf-d DNA; Publication No.: WO\/2003\/093419; PCT\/US2003\/013350; (c) eosinophil cationic protein (ECP) as a tumor marker for malignant tumors; Publication No.: WO\/2019\/219705; PCT\/EP2019\/062378. VH: Honoraria: Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, AstraZeneca. Consulting: Merck, Amgen, Roche, Sanofi, SIRTEX, BMS; MSD, Novartis, Boehringer Ingelheim, Servier, Pierre-Fabre, Celgene, Terumo. Research funding (for the institution): Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, Sirtex, Bayer, Servier. Travel accommodation expenses: Merck, Roche, Amgen, SIRTEX, Bayer, Servier. SB: Consulting and advisory role: Celgene, Servier, Incyte, Fresenius, Janssen-Cilag, AstraZeneca, MSD, BMS; Honoraria: Celgene, Servier, MSD. CBW: CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, Taiho; served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire\/Baxalta, Rafael Pharmaceuticals, RedHill, Roche; has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier, Taiho and research grants (institutional) by Roche. CBW serves as an officer for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft internistische Onkologie (AIO) and is a member of the EU Commission expert group: Mission Board for cancer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted with the principles of the Declaration of Helsinki and with the guideline for good clinical practice. The study was approved by the ethic committee of the Medical Faculty of the Ludwig-Maximilians-University Munich (Reference number: 21-0869).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}